A New Flu Drug Works Well Although It Doesn’t Target the Flu

Each year many elderly and immunocompromised people die from the flu causing them to go into respiratory failure. This is because a thin layer of cells (microvascular endothelium) that form a barrier between your circulatory and respiratory system becomes damaged. Fluids then leak into your lungs causing acute respiratory distress syndrome (ARDS), which results in death from something like drowning.

Thanks to research from a large research team from the University of Toronto headed by Warren L. Lee and Zeca Oliveira, there’s now a new flu treatment, Vasculotide. Instead of fighting the flu, it concentrates on stopping the fluid from leaking into your lungs. This buy your body’s immune system time to outlast the virus and recover.

Since this treatment works really well and isn’t an immune system booster, the research team has applied for a patent. Vasculotide inhibits the flu’s “downstream” effects. As such, the immune system doesn’t get stronger, but it does get more time, which could make all the difference.

Leave a Reply